Founded in 2021, Veloxity Labs is a bioanalytical contract research organization whose primary goal is to expedite scientific timeframes without sacrificing quality. Built as an employee-owned company, it operates with a culture of urgency and a flexible capacity model that allows for rapid, high-quality data delivery. The company supports pharmaceutical, biotech, and animal health activities at the discovery, preclinical, and clinical stages with a focus on LC-MS/MS bioanalysis.

Pharmacokinetics, method development, regulatory compliance, and innovative studies including tiny and big molecules, such as peptides and biomarkers, are among its areas of expertise. Veloxity Labs guarantees accuracy and dependability by using microsampling technology and adhering to international standards like GLP, GCP, and ICH M10. Supported by a staff with decades of experience in the field, the company presents itself as a partner that helps clients advance their research effectively by combining scientific rigor, operational speed, and flexibility.

Core Services at Veloxity Labs

LC-MS Bioanalysis

Veloxity Labs' LC-MS bioanalysis focuses on producing accurate and trustworthy data to assist drug development decisions at various phases. Direct engagement with seasoned scientists who assist in developing bioanalytical strategies for various projects, from early discovery to post-approval investigations, is the foundation of the service. It ensures versatility across research standards by supporting a broad range of biological sample types, such as plasma, whole blood, serum, cerebrospinal fluid, urine, and tissues.

Method creation, validation, and sample analysis are all included in the service, along with thorough reporting to ensure accuracy and legal compliance. Also, Veloxity conducts both controlled and unregulated bioanalysis in accordance with standards like 21 CFR and ICH M10. The lab also deals with large and small compounds, including complex biologics such as antibody-drug conjugates and monoclonal antibodies. This service guarantees high-quality, decision-ready data throughout the drug development lifecycle due to its proficiency with unique biomarkers and sophisticated LC-MS procedures.

Microsampling Bioanalytical Services

Veloxity Labs' microsampling bioanalytical services are created with a patient-centric approach that enhances study participation and data collection. High-throughput sampling made possible by this technique can frequently be carried out outside of conventional clinical settings, such as at home. Microsampling enables more frequent sampling time points and wider participation from a variety of patient populations by lessening the physical strain on patients.

The service uses a variety of advanced microsampling technologies, including capillary sampling systems, Tasso, Mitra®, and dried blood spot (DBS) methods. These techniques make it possible to collect precise samples with fewer amounts while preserving the consistency and quality of the data.  By allowing for greater datasets, this method not only improves study design but also increases patient convenience. Microsampling serves contemporary clinical and research settings where efficiency, accessibility, and data reliability are equally crucial by combining flexibility and precision.

Pharmacokinetic (PK) and Toxicokinetic (TK) Analysis

Veloxity Labs offers pharmacokinetic (PK) and toxicokinetic (TK) analysis using a highly automated and streamlined approach that is intended to be accurate and quick. The company generates results in minutes instead of hours by directly integrating PK/TK analysis with bioanalytical data using Aplos NCA (Non-Compartmental Analysis). The amount of time spent manually formatting, importing, and reporting data is greatly decreased as a result.

The solution provides quick, reliable insights that enhance well-informed decision-making and shorten project durations. Veloxity reduces errors and guarantees reliable, superior results by automating intricate analytical procedures. The workflow prioritizes data security and integrity in addition to speed, with controlled systems that protect sensitive data throughout the analytical process. All things considered, our service makes it possible for researchers to quickly obtain accurate PK/TK parameters, increasing productivity and maintaining the course of development initiatives.

Leading the industry in peptide & GLP-1 bioanalysis

High-Quality Peptide Bioanalysis with LC–MS/MS

Veloxity Labs supports early-phase drug development initiatives with high-quality peptide bioanalysis using LC-MS/MS. Peptide therapies are becoming more popular in fields like endocrine disorders, oncology, and medical imaging, even though GLP-1 receptor agonists are now receiving the most interest. To keep research on schedule, the company uses peptide-focused analytical techniques that combine scientific knowledge with phase-appropriate documentation. Their methodology guarantees that the data produced is dependable and in line with the requirements of development at various phases. Veloxity prioritizes speed, sensitivity, and selectivity in its workflows and has experience with hundreds of peptide programs. This enables sponsors to proceed with assurance, supported by reliable and consistent bioanalytical results. The service helps researchers get high-quality data quickly by managing the complexity of peptide molecules with efficiency.

LC–MS/MS Bioanalysis of Semaglutide & Tirzepatide

Veloxity Labs uses LC–MS/MS bioanalysis of important GLP-1 medications, such as tirzepatide and semaglutide, to showcase its analytical capabilities. Their techniques were created to measure these substances with high sensitivity at low nanogram per milliliter levels in biological matrices like rat plasma and brain tissue. For pharmacological and preclinical research, this level of precision ensures precise detection even at extremely low doses. Strong selectivity and dependability across various sample types and research circumstances are highlighted by the method. Veloxity ensures that results may be relied upon in a variety of research applications by upholding consistency in performance. This proven competence aids drug development efforts that need reliable, high-quality bioanalytical data and validates the lab's proficiency with complicated peptide compounds.

Integrated Platforms Advancing Peptide Programs

Veloxity Labs uses integrated platforms that combine cutting-edge technology and scientific expertise to improve peptide bioanalysis. The company uses advanced technologies like the SCIEX ZenoTOF 8600 HRAM, which allows for faster technique cycles and better resolution while supporting a larger mass range for intact peptides and proteins. In addition, the Thermo Scientific Watson LIMS cloud platform offers centralized data management, guaranteeing traceability and facilitating GLP and GCP-compliant operations. Also, Veloxity uses its VELO workflow standard technology to reduce manual steps, enhance stage coordination, and ensure constant turnaround times. When combined, these technologies provide a structured and efficient environment for peptide studies, enabling programs to advance smoothly while preserving data integrity, operational clarity, and consistent performance across all stages of analysis.

Next-Gen CRO Growth

The company is preparing to scale into a high-speed, technology-based bioanalytical CRO by increasing lab capacity, investing extensively in new instruments, and automating its procedures. A push toward managing increasingly complex biologics, such as peptides and proteins, while boosting throughput and precision is seen in recent expenditures like the ZenoTOF 8600 mass spectrometer and anticipated facility expansion.

Its AI-enabled automation and proprietary VELO™ technology, however, show a long-term focus on fully integrated, end-to-end digital lab operations that can grow without slowing down. This indicates a strategy focused on becoming a quicker, more scalable, and innovation-led partner for pharmaceutical and biotech companies, supporting drug development from early discovery through clinical processes with increasing efficiency and technological sophistication. It is also consistent with high growth, increasing analytical capacity, and expansion into clinical-stage support.

Shane Needham, PhD | Co-Founder, President & CEO

Shane is a reputable industry expert with over 30 years of bioanalysis experience and 200 publications. He is a serial entrepreneur who has started a number of businesses and CROs with a combined ROI of 70,000%. INC 5000 named him a fast-growing firm and named him startup of the year.

His labs have led the industry in small and big molecule bioanalysis, microflow LC-MS/MS, and dried blood spot analysis under his leadership. Shane serves on the boards of many companies and organizations, assisting them in making decisions pertaining to science and business. He is a frequently invited speaker, TED Talk presenter, author, and professional witness in analytical chemistry.

We're a bioanalytical contract research organization (CRO) specializing in services to help you develop therapeutics to treat disease.